Compare Aurora Cannabis Inc (ACB) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

VCIT trades at $82.39 with minimal daily movement (+0.06%) amid bearish technical signals from moving averages. The ETF maintains a competitive 0.03% expense ratio and approximately 5.17% SEC yield, positioning it as a cost-effective intermediate-term corporate bond option. Recent dividend distributions of $0.33-$0.34 highlight consistent income generation, though technical indicators show 14 sell signals against 2 buy signals.

Outlook remains cautious due to bearish technical momentum and corporate bond market sensitivity to interest rate changes. The fund's low-cost structure and steady yield appeal to income-focused investors, but potential volatility from Federal Reserve policy shifts presents near-term risk. Current levels near support at $82 require monitoring for breakdown confirmation.